The committee met in November to discuss the future of vitamin K2 science and health benefits.
Vitamin K2 ingredient supplier Gnosis by Lesaffre (Marcq-en-Baroeul, France) has added two new members to its Vit K2 Scientific Advisory Committee (K2SAC), established earlier this year. The committee also held its inaugural meeting on November 17 in Lille, France.
The two new K2SAC members are Stefanos Roumeliotis, MD, from AHEPA University Hospital in Greece, department of nephrology. According to a press release, Roumeliotis “specializes in chronic disease research and statistical analysis and is driving the MenaQ7 K2 VIKIPEDIA study.” MenaQ7 is Gnosis by Lesaffre’s vitamin K2 brand.
The second new member is Sola Bahous, MD, of the Lebanese American University School of Medicine, who “offers expertise including arterial stiffness, pulse wave velocity, hypertension, and renal/kidney failure, and is immersed in the novel migraine study with MenaQ7 vitamin K2.”
Gnosis by Lesaffre calls K2SAC the world’s first scientific advisory committee whose focus is the research and technical advancement of vitamin K2.
K2SAC held its inaugural meeting in France. The theme of the meeting was to explore the latest research and emerging health areas and applications for vitamin K2.
“We are truly excited about the realm of new users for K2 that the scientific advisory committee will incubate, resulting in more promising research,” stated Jean-Francois Jeanne, manager of Gnosis by Lesaffre’s substantiation and applications team, in a press release.